Skip to content

Effect of Local Anesthesia in Patients With Marginal Periodontitis Undergoing Scaling and Root Planning

Effect of Local Anesthesia in Patients With Marginal Periodontitis Undergoing Scaling and Root Planning

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01878864
Enrollment
12
Registered
2013-06-17
Start date
2012-11-30
Completion date
2013-06-30
Last updated
2015-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain and Discomfort During Scaling and Root Planning of Patients With, Periodontitis

Keywords

Pain, Discomfort, Periodontitis, Scaling and Root Planning, Visual Analogue Scale, McGills Pain Questionnaire

Brief summary

A randomised cross-over study comparing two methods of local anaesthesia for patients diagnosed with periodontitis undergoing scaling and root planning. 40 patients will be included in the study, which aims to demonstrate that the effect of a bupivacaine lozenge is non-inferior to lidocaine-adrenalin injections.

Detailed description

40 periodontitis patients undergoing scaling and root planning (SRP) will be randomised to receive local anaesthesia by either a bupivacaine lozenge or lidocaine-adrenalin injection at their first visit. At the following visit, the patients will receive the opposite treatment. At each visit the patient will evaluate pain before, during and after SRP by: * Visual Analog Scale (VAS) 0-10 where 0 = no pain, 10 = extreme pain. * McGills Pain Questionnaire (MPQ), which gives a qualitative pain profile. At each visit the patient will evaluate discomfort before, during and after the SRP by: \- Visual Analog Scale (VAS) 0-10 where 0 = no discomfort, 10 = extreme discomfort. Additionally the patient assesses the comfort of administration of the two local anaesthesia as well as the taste of the bupivacaine lozenge. The investigator also evaluates the scaling procedure.

Interventions

DRUGLidocaine-adrenalin injection

Sponsors

Ove Andersen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients diagnosed as having, respectively periodontitis marginalis adulta progressiva lenta and periodontitis marginalis adulta progressiva rapid in the hygiene phase, where depurations are repeated within a short timeframe * Age between 18 and 80 years * Ability to speak, read and understand danish * Ability to give oral and written consent

Exclusion criteria

* Known allergy to bupivacaine or other local anaesthetics of the amide type * Other gingival infections (eg lichen planus) * Pregnancy -if in doubt a pregnancy test will be made * Breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
To demonstrate a non-inferior effect on pain and discomfort during scaling and root planning by a bupivacaine lozenge in comparison to lidocaine-adrenalin injections.Day 1Pain and discomfort are measured immediately after the scaling and root planning procedure Level of pain: -Visual Analog Scale (VAS) 0-10 where 0 = no pain, 10 = extreme pain

Secondary

MeasureTime frameDescription
Investigator evaluation of the scaling procedureDay 1After the scaling and root planning the investigator evaluates the scaling procedure by a questionnaire
Patient assessment of the two pharmaceutical formulationsDay 1After the scaling procedure the patient assesses the two pharmaceutical formulations by a questionnaire
To demonstrate a non-inferior effect on pain and discomfort during scaling and root planning by a bupivacaine lozenge in comparison to lidocaine-adrenalin injections.Daiy 1Pain and discomfort are measured immediately after the scaling and root planning procedure Level of pain: -McGills Pain Questionnaire (MPQ), which gives a qualitative pain profile

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026